In a patient with atrial fibrillation, should amlodipine be used for rhythm control?

Amlodipine Should NOT Be Used for Rhythm Control in Atrial Fibrillation

Amlodipine is not indicated for rhythm control in atrial fibrillation and should not be used for this purpose. Amlodipine is a dihydropyridine calcium channel blocker approved only for hypertension and angina—it has no antiarrhythmic properties and does not restore or maintain sinus rhythm 1.

Why Amlodipine Fails as Rhythm Control

The FDA label explicitly states that amlodipine "does not change sinoatrial nodal function or atrioventricular conduction" and "did not alter electrocardiographic intervals or produce higher degrees of AV blocks" 1. This means:

• No effect on atrial rhythm: Amlodipine cannot convert AF to sinus rhythm
• No antiarrhythmic activity: It lacks the electrophysiologic properties needed for rhythm control
• Wrong drug class: Dihydropyridine calcium channel blockers are vasodilators, not antiarrhythmics

What Amlodipine Actually Does (and Doesn't Do)

Amlodipine may actually be counterproductive in AF management. Research shows that compared to drugs with rhythm control properties:

• Valsartan reduced new-onset AF by 16% compared to amlodipine (3.67% vs 4.34%, p=0.0455) 2
• Losartan plus amiodarone prevented AF recurrence in 87% of patients vs only 61% with amlodipine plus amiodarone 3
• Valsartan/amlodipine combinations were superior to atenolol/amlodipine, but the benefit came from valsartan, not amlodipine 4

Correct Approach to Rhythm Control in AF

First-Line Rhythm Control Agents

According to current guidelines 5, 6, 7, 8:

For patients WITHOUT structural heart disease:

• Flecainide
• Propafenone
• Sotalol

For patients WITH heart failure:

• Amiodarone (first choice) 6, 9, 8
• Dofetilide (alternative)

For patients WITH coronary artery disease:

• Sotalol (if no heart failure)
• Amiodarone (if heart failure present)
• Dofetilide

For patients WITH hypertension and LVH (wall thickness ≥1.4 cm):

• Amiodarone (first-line due to safety) 10

Rate Control vs Rhythm Control Decision

Rate control is actually preferred for most patients 5. The 2003 guideline states: "Rate control with chronic anticoagulation is the recommended strategy for the majority of patients with atrial fibrillation" (Grade 2A) 5.

Rate control uses:

• Beta blockers (atenolol, metoprolol)
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) 5, 6, 7
• Digoxin (only for rest, not exercise)

Note that non-dihydropyridine calcium channel blockers (diltiazem, verapamil) work for rate control, but amlodipine is a dihydropyridine and lacks AV nodal blocking effects 6, 7.

Critical Pitfall to Avoid

Do not confuse calcium channel blocker classes. The 2014 AHA/ACC/HRS guideline clearly distinguishes:

• Non-dihydropyridine CCBs (diltiazem, verapamil): Recommended for rate control (Class I) 6, 11, 9
• Dihydropyridine CCBs (amlodipine): No role in AF rhythm or rate control

Bottom Line Algorithm

1. For rhythm control: Use antiarrhythmic drugs (flecainide, propafenone, sotalol, amiodarone, dofetilide) based on structural heart disease presence 5, 6, 8

2. For rate control: Use beta blockers or non-dihydropyridine CCBs (diltiazem/verapamil), NOT amlodipine 5, 6, 7

3. Amlodipine's only role: Treat concurrent hypertension as an adjunct, but never as primary AF therapy

4. Always anticoagulate based on CHA₂DS₂-VASc score regardless of rhythm vs rate strategy 5, 6